Jeffrey W. Henderson - 25 Apr 2024 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
Director
Signature
/s/ James Oehler, Attorney-in-Fact
Issuer symbol
HALO
Transactions as of
25 Apr 2024
Net transactions value
$0
Form type
4
Filing time
29 Apr 2024, 17:56:55 UTC
Previous filing
11 Mar 2024
Next filing
07 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Award $0 +6,501 +14% $0.000000 53,611 25 Apr 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Option to Purchase Common Stock Award $0 +8,804 $0.000000 8,804 25 Apr 2024 Common Stock 8,804 $38.46 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders.
F2 Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders.